Sensitization, glutamate, and the link between migraine and fibromyalgia

Current Pain and Headache Reports

Volumn 11, Issue 5, 2007, Pages 343-351

  Sarchielli, Paola ^a   di Filippo, Massimiliano ^b   Nardi, Katiuscia ^b   Calabresi, Paolo ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANALGESIC AGENT; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DOPAMINE 2 RECEPTOR; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; KETAMINE; MAGNESIUM; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; PLACEBO; TRIPTAN DERIVATIVE;

ANALGESIC ACTIVITY; CEREBROSPINAL FLUID; CHRONIC PAIN; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG RECEPTOR BINDING; FIBROMYALGIA; HUMAN; LOW DRUG DOSE; MIGRAINE; NEUROPATHIC PAIN; NOCICEPTIVE RECEPTOR; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SENSITIZATION; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT;

CENTRAL NERVOUS SYSTEM; FIBROMYALGIA; GLUTAMIC ACID; HUMANS; MIGRAINE DISORDERS; PERIPHERAL NERVOUS SYSTEM;

EID: 34848883362     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-007-0216-2     Document Type: Review

References (98)

1. Silberstein SD: Migraine pathophysiology and its clinical implications. Cephalalgia 2004, 24(Suppl 2):2-7.
2. Price DD, Staud R: Neurobiology of fibromyalgia syndrome. J Rheumatol Suppl 2005, 75:22-28.
3. Vadivelu N, Sinatra R: Recent advances in elucidating pain mechanisms. Curr Opin Anaesthesiol 2005, 18:540-547.
4. Coderre TJ, Katz J: Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 1997, 20:404-419.
5. Melzack R, Coderre TJ, Katz J, Vaccarino AL: Central neuroplasticity and pathological pain. Ann N Y Acad Sci 2001, 933:157-174.
6. Woolf CJ: Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology 2007, 106:864-867.
7. Herrero JF, Laird JM, Lopez-Garcia JA: Wind-up of spinal cord neurons and pain sensation: much ado about something? Prog Neurobiol 2000, 61:169-203.
8. Arendt-Nielsen L, Petersen-Felix S: Wind-up and neuroplasticity: is there a correlation to clinical pain? Eur J Anaesthesiol Suppl 1995, 10:1-7.
9. Li J, Simone DA, Larson AA: Windup leads to characteristics of central sensitization. Pain 1999, 79:75-82.
10. Ji RR, Woolf CJ: Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001, 8:1-10.
11. Cervero F: Spinal cord mechanisms of hyperalgesia and allodynia: role of peripheral input from nociceptors. Prog Brain Res 1996, 113:413-422.
12. Price DD: Selective activation of A-delta and C nociceptive afferents by different parameters of nociceptive heat stimulation: a tool for analysis of central mechanisms of pain. Pain 1996, 68:1-3.
13. Woolf, CJ, Salter MW: Neuronal plasticity: increasing the gain in pain. Science 2000, 288:1765-1769.
14. Goadsby PJ: Migraine, allodynia, sensitisation and all of that... Eur Neurol 2005, 53(Suppl 1):10-16.
15. Meeus M, Nijs J: Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 2007, 26:465-473.
16. Le Goff P: Is fibromyalgia a muscle disorder? Joint Bone Spine 2006, 73:239-242.
17. Ruster M, Franke S, Spath M, et al.: Detection of elevated N epsilon-carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia. Scand J Rheumatol 2005, 34:460-463.
18. Staud R, Rodriguez ME: Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol 2006, 2:90-98.
19. Arendt-Nielsen L, Graven-Nielsen T: Central sensitization in fibromyalgia and other musculoskeletal disorders. Curr Pain Headache Rep 2003, 7:355-361.
20. Hurtig IM, Raak RI, Kendall SA, et al.: Quantitative sensory testing in fibromyalgia patients and in healthy subjects: identification of subgroups. Clin J Pain 2001, 17:316-322.
21. Sorensen J, Graven-Nielsen T, Henriksson KG, et al.: Hyperexcitabitity in fibromyalgia. J Rheumatol 1998, 25:152-155.
22. Desmeules JA, Cedraschi C, Rapiti E, et al.: Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003, 48:1420-1429.
23. Petzke F, Clauw DJ, Ambrose K, et al.: Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003, 105:403-413.
24. Staud R, Vierck CJ, Cannon RL, et al.: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91:165-175.
25. Price DD, Staud R, Robinson ME, et al.: Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 2002, 99:49-59.
26. Staud R, Cannon RC, Mauderli AP, et al.: Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain 2003, 102:87-95.
27. Staud R, Price DD, Robinson ME, et al.: Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain 2004, 110:689-696.
28. Gobel H, Weigle L, Kropp P, Soyka D: Pain sensitivity and pain reactivity of pericranial muscles in migraine and tension-type headache. Cephalalgia 1992, 12:142-151.
29. Jensen R, Rasmussen BK, Pedersen B, Olesen J: Muscle tenderness and pressure pain thresholds in headache. A population study. Pain 1993, 52:193-199.
30. Strassman AM, Raymond SA, Burstein R: Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384:560-564.
31. Burstein R: Deconstructing migraine headache into peripheral and central sensitization. Pain 2001, 89:107-110.
32. Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614-624.
33. Mathew NT, Kailasam J, Seifert T: Clinical recognition of allodynia in migraine. Neurology 2004, 63:848-852.
34. Ashkenazi A, Silberstein S, Jakubowski M, Burstein R: Improved identification of allodynic migraine patients using a questionnaire. Cephalalgia 2007, 27:325-329.
35. Kitaj MB, Klink M: Pain thresholds in daily transformed migraine versus episodic migraine headache patients. Headache 2005, 45:992-998.
36. Cooke L, Eliasziw M, Becker WJ: Cutaneous allodynia in transformed migraine patients. Headache 2007, 47:531-539.
37. Ashkenazi A, Sholtzow M, Shaw JW, et al.: Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia 2007, 27:111-117.
38. Burstein R, Currer MF, Yarnitsky D: The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123:1703-1709.
39. Burstein R, Jakubowski M: Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004, 55:27-36.
40. Levy D, Jakubowski M, Burstein R: Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 2004, 101:4274-4279.
41. Lainez M: Clinical benefits of early triptan therapy for migraine. Cephalalgia 2004, 24(Suppl 2):24-30.
42. Dodick D, Silberstein S: Central sensitization theory of migraine: clinical implications. Headache 2006, 46(Suppl 4): S182-S191.
43. Jakubowski M, Levy D, Goor-Aryeh I, et al.: Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005, 45:850-861.
44. Liu H, Wang H, Sheng M, et al.: Evidence for presynaptic N-methyl-D-aspartate autoreceptors in the spinal cord dorsal horn. Proc Natl Acad Sci U S A 1994, 91:8383-8387.
45. Hwang SJ, Pagliardini S, Rustioni A, Valtschanoff JG: Presynaptic kainate receptors in primary afferents to the superficial laminae of the rat spinal cord. J Comp Neurol 2001, 436:275-289.
46. Lu CR, Hwang SJ, Phend KD, et al.: Primary afferent terminals that express presynaptic NR1 in rats are mainly from myelinated, mechanosensitive fibers. J Comp Neurol 2003, 460:191-202.
47. Lu CR, Hwang SJ, Phend KD, et al.: Primary afferent terminals in spinal cord express presynaptic AMPA receptors. J Neurosci 2002, 22:9522-9S29.
48. Engelman HS, MacDermott AB: Presynaptic ionotropic receptors and control of transmitter release. Nat Rev Neurosci 2004, 5:135-145.
49. Kerchner GA, Wang GD, Qiu CS, et al.: Direct presynaptic regulation of GABA/glycine release by kainate receptors in the dorsal horn: an ionotropic mechanism. Neuron 2001, 32:477-488.
50. Kerchner GA, Wilding TJ, Huettner JE, Zhuo M: Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn. J Neurosci 2002, 22:8010-8017.
51. Wilding TJ, Huettner JE: Functional diversity and developmental changes in rat neuronal kainate receptors. J Physiol 2001, 532:411-421.
52. Lee CJ, Bardoni R, Tong CK, et al.: Functional expression of AMPA receptors on central terminals of rat dorsal root ganglion neurons and presynaptic inhibition of glutamate release. Neuron 2002, 35:135-146.
53. Lee CJ, Labrakakis C, Joseph DJ, Macdermott AB: Functional similarities and differences of AMPA and kainate receptors expressed by cultured rat sensory neurons. Neuroscience 2004, 129:35-48.
54. Bardoni R, Torsney C, Tong CK, et al.: Presynaptic NMDA receptors modulate glutamate release from primary sensory neurons in rat spinal cord dorsal horn. J Neurosci 2004, 24:2774-2781.
55. Lu CR, Willcockson HH, Phend KD, et al.: Ionotropic glutamate receptors are expressed in GABAergic terminals in the rat superficial dorsal horn. J Comp Neurol 2005, 486:169-178.
56. Thompson SW, Woolf CJ, Sivilotti LG: Small-caliber afferent inputs produce a heterosynaptic facilitation of the synaptic responses evoked by primary afferent A-fibers in the neonatal rat spinal cord in vitro. J Neurophysiol 1993, 69:2116-2128.
57. Lu WY, Xiong ZG, Lei S, et al.: G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci 1999, 2:331-338.
58. Mannion RJ, Costigan M, Decosterd I, et al.: Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. Proc Natl Acad Sci U S A 1999, 96:9385-9390.
59. Sandkuhler J, Chen JG, Cheng G, Randic M: Low-frequency stimulation of afferent Adelta-fibers induces long-term depression at primary afferent synapses with substantia gelatinosa neurons in the rat. J Neurosci 1997, 17:6483-6491.
60. South SM, Kohno T, Kaspar BK, et al.: A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. J Neurosci 2003, 23:5031-5040.
61. Fang L, Wu J, Lin Q, Willis WD: Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization. J Neurosci 2002, 22:4196-4204.
62. Garry EM, Moss A, Delaney A, et al.: Neuropathic sensitization of behavioral reflexes and spinal NMDA receptor/CaM kinase II interactions arc disrupted in PSD-95 mutant mice. Curr Biol 2003, 13:321-328.
63. Ji RR, Baba H, Brenner GJ, Woolf CJ: Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 1999, 2:1114-1119.
64. Randic M, Jiang MC, Cerne R: Long-term potentiation and long-term depression of primary afferent neurotransmission in the rat spinal cord. J Neurosci 1993, 13:5228-5241.
65. Mitsikostas DD, Sanchez del Rio M, Waeber C, et al.: The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 1998, 76:239-248.
66. Larson AA, Giovengo SL, Russell IJ, Michalek JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000, 87:201-211.
67. Gallai V, Alberti A, Gallai B, et al.: Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia 2003, 23:166-174.
68. Sarchielli P, Alberti A, Floridi A, Gallai V: Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001, 57:132-134.
69. Sarchielli P, Gallai V: Nerve growth factor and chronic daily headache: a potential implication for therapy. Expert Rev Neurother 2004, 4:115-127.
70. Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564-1569.
71. Sarchielli P, Alberti A, Gallai B, et al.: Brain-derived neurotrophic factor in cerebrospinal fluid of patients with chronic daily headache: relationship with nerve growth factor and glutamate levels. J Headache Pain 2002, 3:129-135.
72. Pezet S, McMahon SB: Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006, 29:507-538.
73. Sarchielli P, Mancini ML, Floridi A, et al.: Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007, In press.
74. Kerr BJ, Bradbury EJ, Bennett DL, et al.: Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci 1999, 19:5138-5148.
75. Merighi A, Carmignoto G, Gobbo S, et al.: Neurotrophins in spinal cord nociceptive pathways. Prog Brain Res 2004, 146:291-321.
76. Peres MF, Zukerman E, Senne Soares CA, et al.: Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004, 24:735-739.
77. Woolf CJ, Thompson SW: The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991, 44:293-299.
78. Dickenson AH, Sullivan AF: Differential effects of excitatory amino acid antagonists on dorsal horn nociceptive neurones in the rat. Brain Res 1990, 506:31-39.
79. Ren K, Hylden JL, Williams GM, et al.: The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioural hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. Pain 1992, 50:331-344.
80. Ren K, Dubner R: NMDA receptor antagonists attenuate mechanical hyperalgesia in rats with unilateral inflammation of the hindpaw. Neurosci Lett 1993, 163:22-26.
81. Ma QP, Woolf CJ: Noxious stimuli induce an N-methyl-D-aspartate receptor-dependent hypersensitivity of the flexion withdrawal reflex to touch: implications for the treatment of mechanical allodynia. Pain 1995, 61:383-390.
82. Sorensen J, Bengtsson A, Backman E, et al.: Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995, 24:360-365.
83. Henriksson KG, Sorensen J: The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia. Rheum Dis Clin North Am 2002, 28:343-351.
84. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al.: Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:483-491.
85. Cohen SP, Verdolin MH, Chang AS, et al.: The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain 2006, 7:391-398.
86. Guedj E, Cammilleri S, Colavolpe C, et al.: Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging 2007, In press.
87. Wood PB: A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. J Pain 2006, 7:611-614.
88. Staud R, Vierck CJ, Robinson ME, Price DD: Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain 2005, 6:323-332.
89. Fusco BM, Colantoni O, Giacovazzo M: Alteration of central excitation circuits in chronic headache and analgesic misuse. Headache 1997, 37:486-491.
90. Nicolodi M, Sicuteri F: Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Clin Pharmacol Res 1995, 15:181-189.
91. Nicolodi M, Del Bianco PL, Sicuteri F: Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse. Int J Clin Pharmacol Res 1997, 17:97-100.
92. Nicolodi M, Sicuteri F: Negative modulators of excitatory amino acids in episodic and chronic migraine: preventing and reverting chronic migraine. Special lecture 7th INWIN Congress. Int J Clin Pharmacol Res 1998, 18:93-100.
93. Brown DG, Krupp JJ: N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr Top Med Chem 2006, 6:749-770.
94. Gogas KR: Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006, 6:68-74.
95. Szekely JI, Torok K, Mate G: The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr Pharm Des 2002, 8:887-912.
96. Planells-Cases R, Lerma J, Ferrer-Montiel A: Pharmacological intervention at ionotropic glutamate receptor complexes. Curr Pharm Des 2006, 12:3583-3596.
97. Varney MA, Gereau RW: Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets CNS Neurol Disord 2002, 1:283-296.
98. Ritzen A, Mathiesen JM, Thomsen C: Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 2005, 97:202-213.